Every individual is different however and your results may vary
In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients-treated with OZEMPIC 0.5 mg and 1 mg, respectively
S.LiL.TsukermanS.GodboleM.PandeyG.et al (2013)
Less gastrointestinal discomfort Less Gastrointestinal Discomfort - Sourced: Vecteezy Compared with the oral version, the injectable semaglutide is usually less likely to cause gastrointestinal discomfort (such as nausea, vomiting, etc.) due to bypassing the gastrointestinal tract, allowing some patients to tolerate it better
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor Tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
Plant-derived bioactive compounds and essential oils show broad therapeutic potential for treating infections, inflammation, and chronic diseases